Article

A case of sterile endophthalmitis after repeated intravitreal bevacizumab injection.

Ophthalmology Department, Yeditepe University Eye Hospital, Istanbul, Turkey.
Journal of Ocular Pharmacology and Therapeutics (Impact Factor: 1.42). 07/2008; 24(3):362-3. DOI: 10.1089/jop.2007.0126
Source: PubMed

ABSTRACT The aim of this study was to describe a case of sterile endophthalmitis after repeated intravitreal bevacizumab injections for the treatment of choroidal neovascularization secondary to angioid streaks.
This study was done as a case report.
A 57-year-old man who received a third injection of intravitreal bevacizumab for the treatment of choroidal neovascularization owing to angioid streaks developed sterile endophthalmitis. The patient's condition improved after hourly topical steroid and antibiotic drops without a sequele.
The intravitreal injection of bevacizumab has the potential for the development of sterile endophthalmitis. The patients should be warned against this possible adverse reaction, especially after repeated injections.

0 Bookmarks
 · 
113 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to report the successful treatment of choroidal neovascularization (CNV) in pathologic myopia (PM) with a posterior sub-Tenon bevacizumab (PSTB; Avastin(®)) injection. The study was a prospective case series including nine eyes of eight patients with PM and CNV. All nine eyes were injected with PSTB (12.5 mg/0.5 ml). Treatment effectiveness was evaluated with optical coherence tomography (OCT). If intraretinal edema or subretinal fluid were detected, injections were repeated after 2 weeks. The main outcome measures were logMAR best-corrected visual acuity (BCVA) and central foveal thickness. The mean follow-up time was 77.56 weeks. BCVA improved by a mean of -0.38 logMAR (>3 lines). The average reduction in absolute central foveal thickness was 25.67 μm. OCT revealed marked CNV volume reduction and fluid-free status in seven eyes. The fluid-free status remained for ≥1 year in these eyes. Fluorescein angiography revealed CNV resolution in three eyes. Corneal stromal penetration of subconjunctival bevacizumab has been demonstrated in animal studies. PSTB may be an equally effective, yet less invasive alternative for the treatment of myopic CNV.
    International Ophthalmology 02/2014; 34(4). DOI:10.1007/s10792-014-9907-y · 0.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of reviewAlthough more than 50% of all uveitis cases have no identifiable cause, certain medications can cause ocular inflammation and are often overlooked. Drug-induced ocular inflammation has increased in frequency with the advent of new bisphosphonates, antitumor necrosis factor biologic agents, and intravitreal triamcinolone and antivascular endothelial growth factor medications. Identification of these inciting drugs will simplify work-up and management of patients with uveitis and improve visual outcomes.Recent findingsThis review briefly focuses on the drugs that have long been known to be strongly associated with uveitis and emphasize new observations about these associations. It will also highlight the newest medications associated with uveitis and scleritis. The strength of the association between each drug and uveitis will be quantified and categorized into definite, probable, possible, and unlikely causes of uveitis utilizing Naranjo's classification criteria.SummaryDrug-induced uveitis has become increasingly recognized in association with a number of commonly used systemic, intraocular, and topical medications. A detailed history is often all that is needed to identify these important, often overlooked, and readily curable causes of uveitis. Most cases of drug-induced uveitis respond promptly to discontinuation of the suspected agent in conjunction with topical corticosteroid and cycloplegic therapy.
    03/2013; 3(1). DOI:10.1186/1869-5760-3-43
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endophthalmitis remains the main complication of intravitreal injections, especially because their repetition multiplicates the risks. Surgical antisepsis is required for the prevention of endophthalmitis, but the benefit/risk ratio of topical antibioprophylaxis has never been demonstrated. In contrast, the selection of resistant bacteria appears to be exponential with the wider use of topical antibioprophylaxis. It seems that more and more operators stop using anibioprophylaxis, provided that the antisepsis is surgical and that the injection is performed in accordance with the rules of good practice.
    Journal francais d'ophtalmologie 01/2013; 36(1):72–75. DOI:10.1016/j.jfo.2012.10.001 · 0.51 Impact Factor